Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation

Highlights • A new scored gliclazide modified release formulation (MR 60 mg) was tested. • The population was 7170 individuals with T2DM followed for 6 months. • Study arms were first-line; add-on; switch from prior oral glucose lowering therapy. • Mean HbA1c decreased 1.6–2.0%; 65% of patients achi...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2016-02, Vol.112, p.50-56
Main Authors: Leiter, Lawrence A, Shestakova, Marina V, Trubitsyna, Natalya P, Piletič, Milivoj, Satman, Ilhan
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Blood Glucose - analysis
Body Mass Index
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Endocrinology & Metabolism
Female
Follow-Up Studies
Gliclazide
Gliclazide - administration & dosage
Glycated Hemoglobin A - analysis
Glycemic control
Humans
Hypoglycemic Agents - administration & dosage
Insulin - therapeutic use
Middle Aged
Time Factors
Treatment adherence
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • A new scored gliclazide modified release formulation (MR 60 mg) was tested. • The population was 7170 individuals with T2DM followed for 6 months. • Study arms were first-line; add-on; switch from prior oral glucose lowering therapy. • Mean HbA1c decreased 1.6–2.0%; 65% of patients achieved HbA1c ≤7.0% (53 mmol/mol). • There was modest weight loss and 0.06% of participants reported hypoglycemic events.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2015.11.001